hrp0084p3-1173 | Thyroid | ESPE2015

Avoidable Thiamazole-Induced Omphalomesenteric Duct Remnants: 20-Year Retrospective Study in Our Hospital

Shinohara Hiroyuki , Komori Koji , Hirobe Seiichi , Hasegawa Yukihiro

Background: Although thiamazole (MMI) is the first-line treatment for non-pregnant women with Graves’ disease, the teratogenic effects of this drug have been confirmed. Surgical anomalies known as ‘major MMI-related anomalies’ include omphalomesenteric duct remnants. This is a common difficulty when attempting to clarify whether there is any association between infrequent surgical anomalies and MMI exposure using data derived from women with Graves’ disease...

hrp0084p3-1071 | Hypo | ESPE2015

A Case of Mild Congenital Hyperinsulinaemia Presenting with Developmental Delay, Complicated by Diazoxide-induced Transient Neutropenia

Abe Yuki , Nishizaki Yoshimi , Sato Seiichi

Background: Congenital hyperinsulinaemic hypoglycaemia (CHI) can cause various degrees of hypoglycaemia in infancy. In mild CHI, unnoticeable recurrent hypoglycaemia may cause deterioration of central neurological functions in patients. We report a case of mild CHI that presented with developmental delay without any previous hypoglycaemic events.Case presentation: An 18-month-old Japanese girl was admitted to our hospital with seizures and unconsciousnes...

hrp0092lb-1 | Late Breaking Posters | ESPE2019

A Trial Investigating the Long-Term Efficacy and Safety of Two Doses of Norditropin® (Somatropin; Recombinant Human Growth Hormone) in Japanese Children with Short Stature Due to Noonan Syndrome Over Four Years of Treatment

Horikawa Reiko , Ogata Tsutomu , Matsubara Yoichi , Yokoya Susumu , Ogawa Yoshihisa , Nishijima Keiji , Endo Takaaki , Ozono Keiichi

Objectives: This trial (NCT01927861) evaluated the growth-promoting effect and safety of Norditropin® (somatropin; recombinant human growth hormone) in Japanese children with short stature due to Noonan syndrome over four years of treatment.Methods: Pre-pubertal children diagnosed with Noonan syndrome were randomized 1:1 to receive Norditropin® 0.033 mg/kg/day or 0.066 mg/kg/day. Change in...

hrp0089p3-p061 | Bone, Growth Plate & Mineral Metabolism P3 | ESPE2018

Incidence Rate of Vitamin D Deficiency in 12-year Old Children in Japan

Koyama Satomi , Naganuma Junko , Kubota Takuo , Ozono Keiichi , Arisaka Osamu , Yoshihara Shigemi

Back ground: The incidence rate of vitamin D deficiency is increasing throughout the world in recent years, but the rate of vitamin D deficiency in Japan is unknown.Aims: We measured the incidence rate of vitamin D deficiency in 12-year old children in Japan.Methods: A total of 492 children (247 boys and 245 girls) from one Japanese community enrolled in this study. At age 12, 25 hydroxyvitamin D (25OHD) were measured in all childr...

hrp0089p3-p166 | Fat, Metabolism and Obesity P3 | ESPE2018

Assessment of Obesity in Children with Achondroplasia and Hypochondroplasia

Nakano Yukako , Kitaoka Taichi , Takeyari Shinji , Ohata Yasuhisa , Kubota Takuo , Ozono Keiichi

Introduction: Obesity is one of common complications in achondroplasia (ACH) and hypochondroplasia (HCH). Obesity can be a risk factor for excessive load on joints or lower spines in aged, worsen sleep apnea and develop a metabolic syndrome. Thus, it is critical to maintain their proper weight from early childhood. ACH specific growth charts and BMI has been used to evaluate their overweight and obesity. Due to disproportional short stature, the assessment by BMI could lead an...

hrp0089p2-p273 | Growth & Syndromes P2 | ESPE2018

Seventeen-year Observation in a Japanese Female Case of Tatton-Brown-Rahman Syndrome: An Overgrowth Syndrome with Intellectual Disability

Miyoshi Yoko , Yamamoto Keiko , Nakano Yukako , Yamamoto Kenichi , Kubota Takuo , Ozono Keiichi

Background: Advances in genetic analysis techniques has greatly contributed to recent discovery of causative genes associated with overgrowth with intellectual disability (OGID). Tatton-Brown-Rahman syndrome (TBRS) (OMIM #615879) was one of them, characterized by tall stature, a distinctive facial appearance, and intellectual disability. This syndrome was first reported in 2014. Thus, long-term clinical courses are unknown. We present our Japanese case with OGID who was diagno...

hrp0084p2-405 | GH & IGF | ESPE2015

SGA Short Stature Bearing with a Novel Nonsense Mutation (p.W1249X) in the IGF1R Gene

Fujimoto Masanobu , Kawashima Yuki , Hamajima Takashi , Miyahara Naoki , Nishimura Rei , Hanaki Keiichi , Kanzaki Susumu

Background: The type I IGF1R plays a role in intrauterine and postnatal growth. Heterozygous IGF1R mutations have been identified in over 20 families. Some of them are linked to the etiology of short stature in previous studies. In addition, we previously reported that a heterozygous nonsense mutation (p.Q1250X) of the IGF1R gene led to decrease IGF1R protein expression through endoplasmic reticulum-associated protein degradation (ERAD) mechanism, resulted in...

hrp0084p3-1001 | Gonads | ESPE2015

Anti-Müllerian Hormone is a Useful Marker of Gonadotoxicity in Girls Treated for Cancer: A Prospective Study

Miyoshi Yoko , Yasuda Kie , Miyamura Takako , Miyashita Emiko , Hashii Yoshiko , Ozono Keiichi

Background: Gonadal dysfunction is one of the major endocrinological late effects among cancer survivors. Chemotherapeutic agents and radiation are so gonadotoxic that ovarian reserve diminishes. Measurement of anti-müllerian hormone (AMH) concentration is useful as a marker of ovarian reserve or gonadal deficiency in female childhood cancer survivors (CCSs), particularly among patients without high gonadotropin levels.Objective and hypotheses: The ...

hrp0092p1-168 | Bone, Growth Plate and Mineral Metabolism (1) | ESPE2019

Genotype-Phenotype Characteristics in Four Families of Type II Collagenopathy in Our Hospital

Yamamoto Kenichi , Kubota Takuo , Takeyari Shinji , Nakano Yukako , Nakayama Hirofumi , Fujiwara Makoto , Ohata Yasuhisa , Kitaoka Taichi , Miyoshi Yoko , Ozono Keiichi

Type II collagenopathy is a generic name of the skeletal dysplasia caused by COL2A1 gene, such as achondrogenesis type II, spondyloepiphyseal dysplasia (SEDC), spondyloepimetaphyseal dysplasia (SEMD). Since this is a rare disease, genotype-phenotype characteristics is still unclear. Here, we describe the genotype-phenotype characteristics of four families of type II collagenopathy in our hospital. Family 1: the proband was 2-year-old girl. She showed severe short stat...

hrp0089fc11.3 | Bone, Growth Plate & Mineral Metabolism 2 | ESPE2018

Evidence for Effects of FGF2 Aptamer in an Achondroplasia Mice Model and an In Vitro Chondrocyte Differentiation System Using Patient-Derived iPS Cells

Ozono Keiichi , Yasuda Kie , Kimura Takeshi , Nakano Yukako , Kitabatake Yasuji , Kubota Takuo , Nonaka Yosuke , Fujiwara Masatoshi , Nakamura Yoshikazu

Achondroplasia (Ach) is a skeletal disorder caused by gain-of-function mutations of FGFR3. Ach patients suffer from various complications such as short stature, foramen magnum stenosis and sleep apnea. Disease-specific treatment is not available at present, although some drugs including a C-type natriuretic peptide analogue have been developed. The mutated FGFR3, G380R, has an elevated activity of the receptor-associated tyrosine kinase, but G380R is further activated...